CCBIO's opinion on current issues.
The concept of precision medicine emerged on US health policy agendas in the early 2010s and has since gained increasing prominence on both sides of the Atlantic, in part replacing the similar concept of personalised medicine. In the more optimistic imaginations of precision cancer care, every...
The days of the Blockbuster drug are over in oncology. The requirement to demonstrate convincing benefit for patients for a new cancer drug in order to license it is driving increasingly rigorous ...
The concept of ELSA - Ethical, Legal and Societal Aspects of Science and Technology - which has been central to the profile of CCBIO since its inception, is gradually becoming supplemented and replaced in Europe by the concept Responsible Research and Innovation (RRI).
The gold standard for a diagnosis of cancer, following clinical and radiological suspicion, has for a long time been the microscopic analysis of simply stained tissue samples. In addition to studying ...
An increasingly older population, new and expensive treatments and higher public expectations will make fair priority setting essential to maintain a sustainable and just health care system. Through the work of CCBIO, functional cancer biomarkers can evolve to play an important role in this process.
Repurposing is a recognized strategy in drug discovery and development where a drug already approved for human use, is screened for new effects and new targets. Repurposing is potentially fruitful because we already know that these drugs are introduced to and distributed in the organism with...
Performing a Pubmed search is an important daily activity for a scientist; however, not everyone realizes that we now have access to more than 26 million publications following the quasi-exponential increase in the number of indexed papers in this database over the last 10 years. Even in our own...
Today, less than 1% of researched cancer biomarkers make it to clinical practice. There are several reasons for this, ranging from the complexities and uncertainties characterizing this field, to methodological shortcomings, or indeed the complicated relationship between Big Pharma and public cancer...
Two major challenges seem to limit contemporary targeted treatment of cancer: i) mapping of tumor clonality at diagnosis and during therapy, and ii) identification of patients responding to immunological check-point inhibitors.
Cancer is a leading cause of death worldwide and a major health challenge; over half of current adults under the age of 65 years will be diagnosed with cancer at some point in their lifetime. ...
There are several dimensions to the economics of biomarkers: including the analysis of the pharmaceutical market, the economic evaluation of biomarkers, and the study of how biomarkers influence behavior.
Health Priorities Should Be Open, Just and Smart
